Amgen And Biolabs LA At The Lundquist Institute Announce Nammi Therapeutics To Receive The Third Amgen Golden Ticket
Biotherapeutics Company to Receive lab Space, Mentoring and Other Benefits
THOUSAND OAKS, Calif., Jan. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticket in Southern California. Nammi Therapeutics will receive one year of lab space at BioLabs LA at The Lundquist Institute (TLI) as well as additional facility benefits and connections to Amgen's scientific and business leaders.
The Amgen Golden Ticket winner was chosen by a team of Amgen scientific leaders at a virtual pitch event. Five finalists pitched their business plans before Amgen's internal committee that evaluated the strength and novelty of their scientific rationale, subject matter expertise and business plan viability. This is the third Amgen Golden Ticket awarded to help accelerate life science startups in Southern California.
Perspectives on announcement:
- "As we announce our third Southern California Golden Ticket winner, it's exciting to see how Amgen's partnership with BioLabs LA at The Lundquist Institute has already made an impact on scientific research in the greater Los Angeles area, helping to accelerate the growth and development of several life-science startups. We look forward to extending this opportunity to Nammi Therapeutics and their exciting work in immuno-oncology." – Alan Russell, Ph.D., vice president of Biologic Therapeutic Discovery at Amgen
- "It has been an honor to work with BioLabs, the Lundquist Institute, and Amgen on the third consecutive Golden Ticket event. After witnessing the success of the first two award recipients (Karma Biotechnologies and Diadem Therapeutics), we cannot wait to see what progress this collaboration with Nammi Therapeutics drives next." – Lindsay Bourgeois, site director, BioLabs LA
- "Nammi is honored to have been chosen as the winner of the Amgen-BioLabs Golden Ticket Award. The material support for our organization is very helpful and having the promise of the Nammi immuno-oncology platform technologies to improve the lives of cancer patients recognized by a leader in the field such as Amgen is even more rewarding. We look forward to working with Amgen and BioLabs as we advance our lead programs and grow our organization." – David R. Stover, Ph.D., president and CEO, Nammi Therapeutics
Amgen supports life science startups through Golden Ticket awards and affiliated engagement in other biotech innovation hubs, including San Francisco, Boston, Singapore and Toronto. Nammi Therapeutics is the 30th Golden Ticket winner since program inception in 2014.